Hyliion Holdings awarded U.S. Navy contract over KARNO power module
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with , delivered to your inbox every week.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
Report – Inter Milan Making Strides In Exhausting Pursuit Of Atalanta Star Forward
Inter Milan informed Atalanta of their second offer for Ademola Lookman earlier today, but have yet to receive a definite response. According to Sportitalia via FCInterNews, La Dea are still expecting a written proposal from the San Siro club. Beppe Marotta met with Luca Precassi during today's League Council and took the occasion to present Inter's second bid. Indeed, after Atalanta turned down their €40 million offer earlier in July, the Nerazzurri have returned with a new package. Inter Milan Making Progress in Talks over Atalanta Star Ademola Lookman BERGAMO, ITALY – JANUARY 21: Ademola Lookman of Atalanta celebrates scoring his team's fourth goal during the UEFA Champions League 2024/25 League Phase MD7 match between Atalanta BC and SK Sturm Graz at Stadio di Bergamo on January 21, 2025 in Bergamo, Italy. (Photo by) As it stands, Inter's new bid, worth €40 million plus another €5 million in add-ons, could do the trick. Though it's still below Atalanta's request, a written proposal will likely get La Dea's seal of approval. Indeed, Ivan Juric's men have urged the San Siro outfit to put their terms on paper before sending their response. Meanwhile, Ademola Lookman is waiting for Atalanta's signal to start packing his bags.
Business Wire
a day ago
- Business Wire
AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate
SEATTLE & HEIDELBERG, Germany--(BUSINESS WIRE)-- AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) to supply drug substance for an investigational four-valent Shigella bioconjugate vaccine at the CDMO's Heidelberg facility. Valneva exclusively licensed the vaccine candidate from LimmaTech Biologics AG, which previously worked with AGC Biologics to establish GMP-compliant manufacturing and quality control of the vaccine's complex protein-polysaccharide conjugates for first-in-human studies. The objective of the new partnership with Valneva is to establish phase II supply relying on the ability of AGC Biologics' Heidelberg site to guide complex molecules through clinical stages. Valneva and LimmaTech announced the launch of a Phase 2 infant study in April, and a Phase 2b Human Challenge Study (CHIM) in November 2024. Shigellosis is the second leading cause of fatal diarrheal disease worldwide, strongly contributing to pediatric morbidity and mortality. It is estimated that up to 165 million infections are due to Shigella, of which 62.3 million occur in children younger than five years. Developing an effective vaccine to prevent this deadly disease is a public health imperative for many areas of the world. "Our site's unique ability to handle complex molecules and multi-valent assets can help this potentially life-saving program reach its next clinical milestone," said Dieter Kramer, Senior Vice President and General Manager, AGC Biologics Heidelberg. "We appreciate Valneva entrusting our team of experts with this challenge and are honored to contribute to efforts that aim to prevent millions of deadly infections in the future." AGC Biologics runs multiple cGMP microbial fermentation lines at its Heidelberg facility. The site has produced biologics products for 40 years. It offers developers freedom-to-operate strain development, proven experience with different bacterial and yeast systems, proprietary plasmid DNA (pDNA) and messenger RNA (mRNA) platforms, large-scale tanks for late-phase protein refolding, the ability to take on early-phase and fast track projects, and late-phase and commercial expertise. To learn more about the microbial system-based biologics, pDNA and mRNA manufacturing site in Heidelberg, visit For more information on AGC Biologics' global CDMO services across all modalities, go to About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit
Miami Herald
a day ago
- Miami Herald
Vaya Space Selected for $1.2M AFWERX Phase II Contract to Advance Hypersonic Propulsion
Hybrid-Fueled Ramjet to Enable Throttleable, Restartable Missile Systems for Enhanced A2/AD Penetration COCOA, FLORIDA / ACCESS Newswire / July 29, 2025 / Vaya Space announces it has been selected by AFWERX for a SBIR Phase II in the amount of $1,236,406 focused on the development of the Hybrid-Fueled Ramjet, a throttleable and restartable hypersonic missile propulsion system, to address the most pressing challenges in the Department of the Air Force (DAF). The Air Force Research Laboratory and AFWERX have partnered to streamline the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) process by accelerating the small business experience through faster proposal to award timelines, changing the pool of potential applicants by expanding opportunities to small business and eliminating bureaucratic overhead by continually implementing process improvement changes in contract execution. The DAF began offering the Open Topic SBIR/STTR program in 2018, which expanded the range of innovations the DAF funded, and now on July 9, 2025, Vaya Space will start its journey to create and provide innovative capabilities that will strengthen the national defense of the United States of America. "This Phase II award represents a significant advancement in hypersonic propulsion and a strong vote of confidence in Vaya's hybrid technology. Our Hybrid-Fueled Ramjet introduces a new class of adaptable missile propulsion; combining throttleability, restart capability, and mission-tailorable thrust to meet the dynamic demands of modern defense. We're proud to help shape the future of strategic capability for the United States," stated Vaya Space Chief Executive Officer Kevin Lowdermilk. The views expressed are those of the author and do not necessarily reflect the official policy or position of the Department of the Air Force, the Department of Defense or the U.S. government. About Vaya Space Vaya Space is a privately owned company based on the Space Coast and leveraging patented Vortex-Hybrid engine technology to disrupt both the Space and Defense markets. Visit for more information. About AFRL The Air Force Research Laboratory, or AFRL, is the primary scientific research and development center for the Department of the Air Force. AFRL plays an integral role in leading the discovery, development and integration of affordable warfighting technologies for our air, space and cyberspace forces. With a workforce spanning across nine technology areas and 40 other operations around the globe, AFRL provides a diverse portfolio of science and technology ranging from fundamental to advanced research and technology development. For more information, visit AFWERX As the innovation arm of the DAF and a directorate within the Air Force Research Laboratory, AFWERX brings cutting-edge American ingenuity from small businesses and start-ups to address the most pressing challenges of the DAF. AFWERX employs approximately 320 military, civilian and contractor personnel at four hubs and sites executing an annual $1.4 billion budget. Since 2019, AFWERX has awarded over 10,400 contracts worth more than $7.24 billion to strengthen the U.S. defense industrial base and drive faster technology transition to operational capability. For more information, visit SOURCE: Vaya Space press release
